AI Insight
This study examines how various excipients (inactive ingredients) can prevent common stability problems in liquid bacteriophage formulations, including adsorption to container surfaces, particle aggregation, and structural damage to the phage particles. The research identifies specific excipient combinations that maintain phage viability and infectivity during storage by protecting the viral structures from physical and chemical degradation. The findings provide evidence-based guidelines for formulating stable liquid phage therapeutics.
Why it matters
As antibiotic resistance grows, bacteriophages represent a promising alternative treatment for bacterial infections. This research addresses a major barrier to phage therapy by improving storage stability, which is critical for commercial development and clinical application of phage-based medicines.
Understand the Science